论文部分内容阅读
目的评价α＿Ｌ＿岩藻糖苷酶（ＡＦｕ）的临床意义。方法应用微量分光光度法检测良、恶性肝病及胃肠道肿瘤３２７例血清ＡＦｕ活性。结果ＡＦｕ以ＨＣＣ组最高（６５４．７±２０４．６μｍｏｌ·Ｌ－１·ｈ－１），明显高于慢性肝炎（４１５．７±１６９．４）、肝硬变（４１２．５±１４６．８）、肝脏良性占位（３９０．４±１４３．１）、胃肠道恶性肿瘤（３９０．８±１７８．３）及正常对照（３８１．９±１１４．５），Ｐ＜０．０１。对ＨＣＣ诊断敏感性、特异性与ＡＦＰ相当，随访１＿５年发现１３例ＡＦｕ升高患者６例在６＿２８月内确诊为ＨＣＣ，早于ＡＦＰ阳性４＿８周。部分良性肝病ＡＦｕ升高均与肝功损害呈平行关系。ＡＦｕ在ＨＣＣ和胃肠道恶性肿瘤无明显重迭，在疗效分析中ＡＦｕ与ＡＦＰ相当，但早于ＡＦＰ１周时间。结论ＡＦｕ对ＨＣＣ特别是对早期ＡＦＰ阴性ＨＣＣ的诊断、鉴别、疗效评价及高危人群监测有重要价值
Objective To evaluate the clinical significance of α_L_fucosidase (AFu). Methods The serum AFu activity in 327 cases of benign and malignant liver diseases and gastrointestinal tumors was detected by microspectrophotometry. Results AFu was highest in the HCC group (654.7±204.6 μmol·L-1·h-1), which was significantly higher than that of chronic hepatitis (415.7±169.4) and cirrhosis (412.5±146.8). ), Liver benign (390.4±143.1), Gastrointestinal cancer (390.8±178.3) and normal control (381.9±114.5), P<0.01. The sensitivity and specificity of HCC diagnosis were comparable to those of AFP. In 1 to 5 years of follow-up, 13 patients with elevated AFu were found to have been diagnosed with HCC within 6-28 months, 4-8 weeks earlier than AFP. The increase of AFu in some benign liver diseases is parallel to the damage of liver function. AFu showed no significant overlap in HCC and gastrointestinal malignancy. AFu was comparable to AFP in efficacy analysis, but earlier than AFP for 1 week. Conclusion AFu has important value in the diagnosis, differential diagnosis, curative effect evaluation and high-risk group monitoring of HCC, especially early AFP-negative HCC